Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment

Next Previous
Search
Trial Profile

Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Tremelimumab (Primary)
  • Indications Advanced breast cancer; Endometrial cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms GUIDE2REPAIR

    • Most Recent Events

    • 12 Feb 2024 Planned End Date changed from 10 Jun 2029 to 10 Aug 2027.
    • 12 Feb 2024 Planned primary completion date changed from 10 Feb 2023 to 10 Aug 2027.
    • 12 Feb 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top